Paolo Denti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1194134/publications.pdf

Version: 2024-02-01

189 papers 5,949 citations

35 h-index 66 g-index

203 all docs 203 docs citations

203 times ranked 5360 citing authors

#	Article	IF	CITATIONS
1	Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients. Pharmacotherapy, 2023, 43, 638-649.	1.2	2
2	Abacavir pharmacokinetics in African children living with HIV: A pooled analysis describing the effects of age, malnutrition and common concomitant medications. British Journal of Clinical Pharmacology, 2022, 88, 403-415.	1.1	2
3	Conservative, surgical, and percutaneous treatment for mitral regurgitation shortly after acute myocardial infarction. European Heart Journal, 2022, 43, 641-650.	1.0	36
4	Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis. Pharmacogenetics and Genomics, 2022, 32, 24-30.	0.7	3
5	Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study. Clinical Infectious Diseases, 2022, 75, 141-151.	2.9	16
6	Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling. Clinical Pharmacokinetics, 2022, 61, 375-386.	1.6	4
7	One dose does not fit all: revising the WHO paediatric dosing tool to include the non-linear effect of body size and maturation. The Lancet Child and Adolescent Health, 2022, 6, 9-10.	2.7	8
8	Concentration–response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy. British Journal of Clinical Pharmacology, 2022, 88, 883-893.	1.1	9
9	Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study. Journal of Antimicrobial Chemotherapy, 2022, 77, 1146-1154.	1.3	15
10	Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa. Journal of Infectious Diseases, 2022, 226, 147-156.	1.9	8
11	Transcatheter lithotripsy to facilitate post-dilatation of underexpanded aortic transcatheter heart valve. European Heart Journal, 2022, 43, 2081-2081.	1.0	1
12	Population pharmacokinetics of ethambutol in African children: a pooled analysis. Journal of Antimicrobial Chemotherapy, 2022, 77, 1949-1959.	1.3	3
13	Population Pharmacokinetics of Antimalarial Naphthoquine in Combination with Artemisinin in Tanzanian Children and Adults: Dose Optimization. Antimicrobial Agents and Chemotherapy, 2022, , e0169621.	1.4	O
14	Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicinâ€resistant tuberculosis. British Journal of Clinical Pharmacology, 2022, 88, 3548-3558.	1.1	8
15	Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2022, , e0226421.	1.4	O
16	Pharmacogenetics of Dolutegravir Plasma Exposure Among Southern Africans With Human Immunodeficiency Virus. Journal of Infectious Diseases, 2022, 226, 1616-1625.	1.9	3
17	Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin. Antimicrobial Agents and Chemotherapy, 2022, 66, .	1.4	5
18	Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	17

#	Article	IF	CITATIONS
19	Is the EuroSCORE II reliable in surgical mitral valve repair? A single-centre validation study. European Journal of Cardio-thoracic Surgery, 2021, 59, 863-868.	0.6	13
20	Constructing a representative inâ€silico population for paediatric simulations: Application to HIVâ€positive African children. British Journal of Clinical Pharmacology, 2021, 87, 2847-2854.	1.1	15
21	Pharmacokinetics and Drugâ€Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping. Clinical Pharmacology and Therapeutics, 2021, 109, 1034-1044.	2.3	20
22	Pharmacokinetic profile of amodiaquine and its active metabolite desethylamodiaquine in Ghanaian patients with uncomplicated falciparum malaria. Malaria Journal, 2021, 20, 18.	0.8	8
23	Dolutegravir pharmacokinetics during co-administration with either artemether/lumefantrine or artesunate/amodiaquine. Journal of Antimicrobial Chemotherapy, 2021, 76, 1269-1272.	1.3	3
24	Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs. Clinical Pharmacokinetics, 2021, 60, 685-710.	1.6	39
25	Long-term results of tricuspid annuloplasty with 3-dimensional-shaped rings: effective and durable!. European Journal of Cardio-thoracic Surgery, 2021, 60, 115-121.	0.6	4
26	Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis. International Journal of Infectious Diseases, 2021, 105, 688-694.	1.5	20
27	Safety and Feasibility of MitraClip Implantation in Patients with Acute Mitral Regurgitation after Recent Myocardial Infarction and Severe Left Ventricle Dysfunction. Journal of Clinical Medicine, 2021, 10, 1819.	1.0	6
28	Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0268720.	1.4	16
29	Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM]. Wellcome Open Research, 2021, 6, 136.	0.9	8
30	A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug–Drug Interactions With Antiretroviral and Antituberculosis Treatment. Clinical Pharmacology and Therapeutics, 2021, 110, 1057-1065.	2.3	5
31	A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis: Results from a Randomized Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1327-1335.	2,5	18
32	Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0239920.	1.4	10
33	Pharmacokinetics and Target Attainment of SQ109 in Plasma and Human-Like Tuberculosis Lesions in Rabbits. Antimicrobial Agents and Chemotherapy, 2021, 65, e0002421.	1.4	12
34	Linezolid Population Pharmacokinetics in South African Adults with Drug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0138121.	1.4	9
35	Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial. Journal of Antimicrobial Chemotherapy, 2021, 76, 3237-3246.	1.3	26
36	Effect of Isoniazid Intake on Ethionamide Pharmacokinetics and Target Attainment in Multidrug-Resistant Tuberculosis Patients. Antimicrobial Agents and Chemotherapy, 2021, 65, e0027821.	1.4	4

#	Article	IF	CITATIONS
37	Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis. Frontiers in Pharmacology, 2021, 12, 722204.	1.6	3
38	Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virusâ€associated tuberculosis. British Journal of Clinical Pharmacology, 2020, 86, 966-978.	1.1	8
39	Real-World Safety and Efficacy of Transcatheter Mitral Valve Repair With MitraClip: Thirty-Day Results From the Italian Society of Interventional Cardiology (Glse) Registry Of Transcatheter Treatment of Mitral Valve RegurgitaTiOn (GIOTTO). Cardiovascular Revascularization Medicine, 2020, 21, 1057-1062.	0.3	23
40	Population Pharmacokinetics and Dosing of Ethionamide in Children with Tuberculosis. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	7
41	Clofazimine pharmacokinetics in patients with TB: dosing implications. Journal of Antimicrobial Chemotherapy, 2020, 75, 3269-3277.	1.3	33
42	Effects of Pregnancy and Isoniazid Preventive Therapy on Mycobacterium tuberculosis Interferon Gamma Response Assays in Women With HIV. Clinical Infectious Diseases, 2020, 73, e3555-e3562.	2.9	9
43	Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review. Journal of Antimicrobial Chemotherapy, 2020, 75, 3433-3457.	1.3	23
44	Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	13
45	Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	5
46	Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF). Trials, 2020, 21, 181.	0.7	14
47	Outcomes of TTVI in Patients With Pacemaker or Defibrillator Leads. JACC: Cardiovascular Interventions, 2020, 13, 554-564.	1.1	32
48	Combined Tricuspid and Mitral VersusÂlsolatedÂMitral Valve RepairÂforÂSevereÂMR and TR. JACC: Cardiovascular Interventions, 2020, 13, 543-550.	1.1	63
49	Population Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Pregnant South African Women with Tuberculosis and HIV. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	20
50	An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	14
51	Commentary on: Transapical aortic perfusion using a deep hypothermic procedure during descending thoracic or thoracoabdominal aortic surgery. Journal of Cardiovascular Surgery, 2020, 61, 129-130.	0.3	0
52	MitraClip for radiotherapy-related mitral valve regurgitation. Hellenic Journal of Cardiology, 2019, 60, 232-238.	0.4	12
53	1-Year Outcomes After Edge-to-Edge Valve Repair for Symptomatic TricuspidÂRegurgitation. JACC: Cardiovascular Interventions, 2019, 12, 1451-1461.	1.1	160
54	A challenging mitral valve anatomy for percutaneous repair with MitraClip: cleft posterior leaflet. European Heart Journal Cardiovascular Imaging, 2019, 20, 1433-1434.	0.5	3

#	Article	IF	CITATIONS
55	Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet, The, 2019, 394, 2002-2011.	6.3	283
56	Transcatheter Versus Medical Treatment of Patients With Symptomatic SevereÂTricuspid Regurgitation. Journal of the American College of Cardiology, 2019, 74, 2998-3008.	1.2	302
57	A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	16
58	Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	14
59	Midâ€term outcomes (up to 5 years) of percutaneous edgeâ€toâ€edge mitral repair in the realâ€world according to regurgitation mechanism: A singleâ€center experience. Catheterization and Cardiovascular Interventions, 2019, 94, 427-435.	0.7	22
60	Anatomic Relationship of the Complex Tricuspid Valve, Right Ventricle, and Pulmonary Vasculature. JAMA Cardiology, 2019, 4, 478.	3.0	43
61	Initial Feasibility Study of a NewÂTranscatheter Mitral Prosthesis. Journal of the American College of Cardiology, 2019, 73, 1250-1260.	1.2	172
62	Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	11
63	Transcatheter or surgical repair for degenerative mitral regurgitation in elderly patients: A propensity-weighted analysis. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 86-94.e1.	0.4	33
64	Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis. Pharmacogenomics, 2019, 20, 225-240.	0.6	32
65	Outcomes After Current Transcatheter Tricuspid Valve Intervention. JACC: Cardiovascular Interventions, 2019, 12, 155-165.	1.1	246
66	A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs. Clinical Pharmacokinetics, 2019, 58, 747-766.	1.6	53
67	Transcatheter Repair of Severe Functional Tricuspid Insufficiency UsingÂaÂMitral Clip System. JACC: Cardiovascular Imaging, 2019, 12, 554-558.	2.3	6
68	Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	19
69	The Tricuspid Valve Relationship WithÂtheÂRight Ventricle and PulmonaryÂVasculature. JACC: Cardiovascular Imaging, 2019, 12, 564-565.	2.3	9
70	Anesthesiologic Management of Patients Undergoing Cardiac Transapical Procedures: Which Challenges in the Modern Era?. Journal of Cardiothoracic and Vascular Anesthesia, 2019, 33, 1883-1889.	0.6	1
71	Lopinavir–ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir–ritonavir without rifampicin: a pharmacokinetic modelling and clinical study. Lancet HIV,the, 2019, 6, e32-e42.	2.1	19
72	Population Pharmacokinetic Properties of Sulfadoxine and Pyrimethamine: a Pooled Analysis To Inform Optimal Dosing in African Children with Uncomplicated Malaria. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	18

#	Article	IF	CITATIONS
73	Delayed Sputum Culture Conversion in Tuberculosis–Human Immunodeficiency Virus–Coinfected Patients With Low Isoniazid and Rifampicin Concentrations. Clinical Infectious Diseases, 2018, 67, 708-716.	2.9	34
74	Effect of genetic variation in <i>UGT1A</i> and <i>ABCB1</i> on moxifloxacin pharmacokinetics in South African patients with tuberculosis. Pharmacogenomics, 2018, 19, 17-29.	0.6	16
75	Beating-Heart Mitral Valve Repair UsingÂaÂNovel ePTFE Cordal ImplantationÂDevice. Journal of the American College of Cardiology, 2018, 71, 25-36.	1.2	71
76	A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400Âmg in Pregnant Women. Clinical Pharmacokinetics, 2018, 57, 1421-1433.	1.6	6
77	Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	37
78	Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	16
79	Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy. Clinical Pharmacokinetics, 2018, 57, 591-599.	1.6	26
80	Transcatheter Tricuspid Valve Repair With a Novel Cinching System. JACC: Cardiovascular Interventions, 2018, 11, e199-e201.	1.1	14
81	Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid. Journal of Antimicrobial Chemotherapy, 2018, 74, 139-148.	1.3	21
82	Transcatheter Mitral Valve Replacement in Patients With Previous Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2018, 11, e006412.	1.4	18
83	The Next Generation Scientist program: capacity-building for future scientific leaders in low- and middle-income countries. BMC Medical Education, 2018, 18, 233.	1.0	17
84	UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	40
85	Drug permeation and metabolism in <i>Mycobacterium tuberculosis</i> : Prioritising local exposure as essential criterion in new TB drug development. IUBMB Life, 2018, 70, 926-937.	1.5	27
86	Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	21
87	Can We Improve Stavudine's Safety Profile in Children? Pharmacokinetics of Intracellular Stavudine Triphosphate with Reduced Dosing. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	3
88	Tricuspid valve imaging. Minerva Cardioangiologica, 2018, 66, 680-690.	1.2	4
89	Compare and contrast tricuspid and mitral valve anatomy: interventional perspectives for transcatheter tricuspid valve therapies. EuroIntervention, 2018, 13, 1889-1898.	1.4	30
90	POPULATION PHARMACOKINETICS OF GENTAMICIN IN PUPPIES DIAGNOSED WITH PARVOVIRUS ENTERITIS. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO2-13-1.	0.0	0

#	Article	IF	Citations
91	Optimising mitral repair in functional regurgitation: transcatheter annuloplasty can counteract left ventricle-mitral ring mismatch. EuroIntervention, 2018, 14, 762-763.	1.4	O
92	Antimalarial Pyrido[1,2- <i>a</i>]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse Model. Journal of Medicinal Chemistry, 2017, 60, 1432-1448.	2.9	36
93	Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets. Aids, 2017, 31, 905-915.	1.0	7
94	Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB. Journal of Antimicrobial Chemotherapy, 2017, 72, 1441-1449.	1.3	38
95	Multimodality imaging of the tricuspid valve with implication for percutaneous repair approaches. Heart, 2017, 103, 1073-1081.	1.2	52
96	Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	28
97	Pharmacokinetics of Sulfadoxine and Pyrimethamine for Intermittent Preventive Treatment of Malaria During Pregnancy and After Delivery. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 430-438.	1.3	23
98	Optimizing Research to Speed Up Availability of Pediatric Antiretroviral Drugs and Formulations. Clinical Infectious Diseases, 2017, 64, 1597-1603.	2.9	26
99	Percutaneous Tricuspid Valve Annuloplasty Under Conscious Sedation (With Only Fluoroscopic and) Tj ETQq1 1 (0.784314 1.1	rgBT /Overlo
100	Transcatheter Treatment of Severe Tricuspid Regurgitation With the Edge-to-Edge MitraClip Technique. Circulation, 2017, 135, 1802-1814.	1.6	313
101	Use of Echocardiography for Guiding Percutaneous Tricuspid Valve Procedures. JACC: Cardiovascular Imaging, 2017, 10, 1194-1198.	2.3	15
102	Reverse Left Ventricular Remodeling CausingÂSevere Mitral Regurgitation After BentallÂProcedure. Annals of Thoracic Surgery, 2017, 103, e85-e86.	0.7	0
103	Response to "Lactation Status and Studies of Pyrimethamine Pharmacokinetics in Pregnancy― CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 731-731.	1.3	3
104	The International Multicenter TriValveÂRegistry. JACC: Cardiovascular Interventions, 2017, 10, 1982-1990.	1,1	175
105	Mitral Valve-in-Ring Implantation With a Dedicated Transcatheter Mitral Valve Replacement System. JACC: Cardiovascular Interventions, 2017, 10, 2012-2014.	1.1	5
106	Systolic anterior motion after mitral valve repair: a predictive computational modelâ€. Interactive Cardiovascular and Thoracic Surgery, 2017, 25, 513-519.	0.5	7
107	Does implantation of a single clip provide reliable durability after transcatheter mitral repair?â€. European Journal of Cardio-thoracic Surgery, 2017, 52, 137-142.	0.6	16
108	Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants. Journal of Antimicrobial Chemotherapy, 2017, 72, 2028-2034.	1.3	9

#	Article	IF	Citations
109	Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients. Journal of Antimicrobial Chemotherapy, 2017, 72, 490-495.	1.3	4
110	Percutaneous bicuspidalization of the tricuspid valve using the MitraClip system. International Journal of Cardiovascular Imaging, 2017, 33, 227-228.	0.7	11
111	Effect of diurnal variation, CYP2B6genotype and age on the pharmacokinetics of nevirapine in African children. Journal of Antimicrobial Chemotherapy, 2017, 72, 190-199.	1.3	10
112	Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis. Clinical Infectious Diseases, 2017, 64, 1350-1359.	2.9	40
113	Mitral valve annuloplasty. , 2017, 2017, .		3
114	The big parade: emerging percutaneous mitral and tricuspid valve devices. EuroIntervention, 2017, 13, AA51-AA59.	1.4	13
115	Treatment Failure, Drug Resistance, and CD4 T-Cell Count Decline Among Postpartum Women on Antiretroviral Therapy in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 31-37.	0.9	23
116	Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 161-168.	0.9	14
117	Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction. Antimicrobial Agents and Chemotherapy, 2016, 60, 487-494.	1.4	61
118	Optimal results immediately after MitraClip therapy or surgical edge-to-edge repair for functional mitral regurgitation: are they really stable at 4 years?. European Journal of Cardio-thoracic Surgery, 2016, 50, 488-494.	0.6	31
119	Effect of mid-dose efavirenz concentrations and CYP2B6 genotype on viral suppression in patients on first-line antiretroviral therapy. International Journal of Antimicrobial Agents, 2016, 47, 466-472.	1.1	25
120	The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children. British Journal of Clinical Pharmacology, 2016, 82, 185-198.	1.1	28
121	HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients. Antimicrobial Agents and Chemotherapy, 2016, 60, 6050-6059.	1.4	25
122	MitraClip therapy and surgical edge-to-edge repair in patients with severe left ventricular dysfunction and secondary mitral regurgitation: mid-term results of a single-centre experience. European Journal of Cardio-thoracic Surgery, 2016, 49, 255-262.	0.6	39
123	Population Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South Africa. Antimicrobial Agents and Chemotherapy, 2016, 60, 1234-1241.	1.4	32
124	What is a "good―result after transcatheter mitral repair? Impact of 2+ residual mitral regurgitation. Journal of Thoracic and Cardiovascular Surgery, 2016, 151, 88-96.	0.4	89
125	Recent developments in percutaneous mitral valve treatment. Expert Review of Cardiovascular Therapy, 2016, 14, 217-228.	0.6	1
126	Percutaneous repair of the tricuspid valve using a novel cinching device: acute and chronic experience in a preclinical large animal model. EuroIntervention, 2016, 12, 918-925.	1.4	11

#	Article	IF	CITATIONS
127	Transcatheter direct mitral annuloplasty with Cardioband: feasibility and efficacy trial in an acute preclinical model. EuroIntervention, 2016, 12, e1428-e1434.	1.4	10
128	Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania. PLoS ONE, 2015, 10, e0141002.	1.1	73
129	Comparison of Outcomes of Percutaneous MitraClip Versus Surgical Repair or Replacement for Degenerative Mitral Regurgitation in Octogenarians. American Journal of Cardiology, 2015, 115, 487-492.	0.7	29
130	Clinical and anatomical predictors of MitraClip therapy failure for functional mitral regurgitation: single central clip strategy in asymmetric tethering. International Journal of Cardiology, 2015, 186, 286-288.	0.8	31
131	Surgical treatment of paravalvular leak: Long-term results in a single-center experience (up to 14) Tj ETQq1 1 0.78	4314 rgBT 0.4	
132	Pharmacokinetics of Efavirenz and Treatment of HIV-1 Among Pregnant Women With and Without Tuberculosis Coinfection. Journal of Infectious Diseases, 2015, 211, 197-205.	1.9	69
133	In vivo efficacy and bioavailability of lumefantrine: Evaluating the application of Pheroid technology. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 97, 68-77.	2.0	23
134	First-in-Man Implantation of a Tricuspid Annular Remodeling Device for Functional Tricuspid Regurgitation. JACC: Cardiovascular Interventions, 2015, 8, e211-e214.	1,1	111
135	A translational $\hat{a} \in \mathbb{R}$ whumanised $\hat{a} \in \mathbb{R}$ porcine model for transcatheter mitral valve interventions: the neo inferior vena cava approach. EuroIntervention, 2015, 11, 92-95.	1.4	9
136	Conventional surgery and transcatheter closure via surgical transapical approach for paravalvular leak repair in high-risk patients: results from a single-centre experience. European Heart Journal Cardiovascular Imaging, 2014, 15, 1161-1167.	0.5	62
137	Do Patients Undergoing MitraClip Implantation Require Routine ICU Admission?. Journal of Cardiothoracic and Vascular Anesthesia, 2014, 28, 1479-1483.	0.6	18
138	Transcatheter treatment of chronic mitral regurgitation with the MitraClip system. Journal of Cardiovascular Medicine, 2014, 15, 173-188.	0.6	9
139	Moxifloxacin Population Pharmacokinetics and Model-Based Comparison of Efficacy between Moxifloxacin and Ofloxacin in African Patients. Antimicrobial Agents and Chemotherapy, 2014, 58, 503-510.	1.4	38
140	Nutritional Supplementation Increases Rifampin Exposure among Tuberculosis Patients Coinfected with HIV. Antimicrobial Agents and Chemotherapy, 2014, 58, 3468-3474.	1.4	51
141	Percutaneous edge-to-edge repair in high-risk and elderly patients with degenerative mitral regurgitation: Midterm outcomes in a single-center experience. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 2743-2750.	0.4	25
142	Afterload Mismatch After MitraClip Insertion for Functional Mitral Regurgitation. American Journal of Cardiology, 2014, 113, 1844-1850.	0.7	48
143	Devices for Mitral Valve Repair. Journal of Cardiovascular Translational Research, 2014, 7, 266-281.	1.1	10
144	First-in-Man Transseptal Implantation of a "Surgical-Like―Mitral Valve Annuloplasty Device for Functional Mitral Regurgitation. JACC: Cardiovascular Interventions, 2014, 7, 1326-1328.	1.1	39

#	Article	IF	CITATIONS
145	Pharmacokinetic evaluation of lisinopril-tryptophan, a novel C-domain ACE inhibitor. European Journal of Pharmaceutical Sciences, 2014, 56, 113-119.	1.9	12
146	Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses. Journal of Antimicrobial Chemotherapy, 2014, 69, 1339-1349.	1.3	53
147	Clinical outcomes of MitraClip for the treatment of functional mitral regurgitation. EuroIntervention, 2014, 10, 746-752.	1.4	97
148	Acute kidney injury following MitraClip implantation in high risk patients: Incidence, predictive factors and prognostic value. International Journal of Cardiology, 2013, 169, e24-e25.	0.8	20
149	TCT-700 Percutaneous Vs Surgical Repair For Degenerative Mitral Regurgitation In Octogenarians Journal of the American College of Cardiology, 2013, 62, B213-B214.	1.2	0
150	The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals [Short communication]. International Journal of Tuberculosis and Lung Disease, 2013, 17, 333-335.	0.6	13
151	A Time-to-Event Pharmacodynamic Model Describing Treatment Response in Patients with Pulmonary Tuberculosis Using Days to Positivity in Automated Liquid Mycobacterial Culture. Antimicrobial Agents and Chemotherapy, 2013, 57, 789-795.	1.4	34
152	Modelâ€based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin. British Journal of Clinical Pharmacology, 2013, 76, 741-751.	1.1	12
153	Pharmacometrics: Opportunity for Reducing Disease Burden in the Developing World: The Case of Africa. CPT: Pharmacometrics and Systems Pharmacology, 2013, 2, 1-4.	1.3	19
154	Population Pharmacokinetics of Lopinavir and Ritonavir in Combination with Rifampicin-Based Antitubercular Treatment in HIV-Infected Children. Antiviral Therapy, 2012, 17, 25-33.	0.6	22
155	The disposition index: from individual to population approach. American Journal of Physiology - Endocrinology and Metabolism, 2012, 303, E576-E586.	1.8	22
156	Population Pharmacokinetic Model for Adherence Evaluation Using Lamivudine Concentration Monitoring. Therapeutic Drug Monitoring, 2012, 34, 481-484.	1.0	10
157	Reduced Antituberculosis Drug Concentrations in HIV-Infected Patients Who Are Men or Have Low Weight: Implications for International Dosing Guidelines. Antimicrobial Agents and Chemotherapy, 2012, 56, 3232-3238.	1.4	91
158	Mitraclip therapy and surgical mitral repair in patients with moderate to severe left ventricular failure causing functional mitral regurgitation: a single-centre experience. European Journal of Cardio-thoracic Surgery, 2012, 42, 920-926.	0.6	85
159	Moxifloxacin Population Pharmacokinetics in Patients with Pulmonary Tuberculosis and the Effect of Intermittent High-Dose Rifapentine. Antimicrobial Agents and Chemotherapy, 2012, 56, 4471-4473.	1.4	30
160	Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics. British Journal of Clinical Pharmacology, 2012, 74, 465-476.	1.1	24
161	Direct access transcatheter mitral annuloplasty with a sutureless and adjustable device: preclinical experience. European Journal of Cardio-thoracic Surgery, 2012, 42, 524-529.	0.6	59
162	TCT-793 Effects of Preoperative Tricuspid Regurgitation on Mitral Regurgitation Treatment with the MitraClip Device in High-Risk Patients. Journal of the American College of Cardiology, 2012, 60, B231.	1.2	1

#	Article	IF	Citations
163	Antimalarial and anticancer activities of artemisinin–quinoline hybrid-dimers and pharmacokinetic properties in mice. European Journal of Pharmaceutical Sciences, 2012, 47, 834-841.	1.9	35
164	Modelâ€based approach to dose optimization of lopinavir/ritonavir when coâ€administered with rifampicin. British Journal of Clinical Pharmacology, 2012, 73, 758-767.	1.1	20
165	Quality of life improvement is maintained up to two years after transcatheter aortic valve implantation in high-risk surgical candidates. EuroIntervention, 2012, 8, 429-436.	1.4	21
166	Transseptal access for MitraClip $\hat{A}^{@}$ procedures using surgical diathermy under echocardiographic guidance. EuroIntervention, 2012, 8, 579-586.	1.4	19
167	Clinical trial experience with the MitraClip catheter based mitral valve repair system. International Journal of Cardiovascular Imaging, 2011, 27, 1155-1164.	0.7	12
168	Trans-apical and trans-axillary percutaneous aortic valve implantation as alternatives to the femoral route: short- and middle-term results. European Journal of Cardio-thoracic Surgery, 2011, 40, 49-55.	0.6	44
169	The <i>SLCO1B1</i> rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications. Antimicrobial Agents and Chemotherapy, 2011, 55, 4122-4127.	1.4	130
170	Alfieri stitch and its impact on mitral clip. European Journal of Cardio-thoracic Surgery, 2011, 39, 807-808.	0.6	23
171	Percutaneous mitral valve repair with the edge-to-edge technique. Multimedia Manual of Cardiothoracic Surgery: MMCTS / European Association for Cardio-Thoracic Surgery, 2010, 2010, mmcts.2009.004002.	0.5	0
172	Neochordae Implantation Made Easy with an Adjustable Device Early Report of Acute and Chronic Animal Experiments. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2010, 5, 287-290.	0.4	3
173	IVGTT glucose minimal model covariate selection by nonlinear mixed-effects approach. American Journal of Physiology - Endocrinology and Metabolism, 2010, 298, E950-E960.	1.8	19
174	Concurrent prophylactic left atrial appendage exclusion: results from a randomized controlled trial pilot studya †. European Journal of Cardio-thoracic Surgery, 2009, 36, 553-557.	0.6	25
175	Quality of life of elderly patients following valve surgery for chronic organic mitral regurgitationâ [†] . European Journal of Cardio-thoracic Surgery, 2009, 36, 261-266.	0.6	28
176	Characterizing multisegment foot kinematics during gait in diabetic foot patients. Journal of NeuroEngineering and Rehabilitation, 2009, 6, 37.	2.4	57
177	Nonlinear Mixed Effects to Improve Glucose Minimal Model Parameter Estimation: A Simulation Study in Intensive and Sparse Sampling. IEEE Transactions on Biomedical Engineering, 2009, 56, 2156-2166.	2.5	14
178	Emergency transfemoral aortic valve-in-valve implantation with the balloon-expandable Edwards–Sapien valve. Journal of Cardiovascular Medicine, 2009, 10, 936-939.	0.6	7
179	Mitral annuloplasty. Multimedia Manual of Cardiothoracic Surgery: MMCTS / European Association for Cardio-Thoracic Surgery, 2009, 2009, mmcts.2008.003640.	0.5	9
180	Glucose Minimal Model population analysis: Likelihood function profiling via Monte Carlo sampling. , 2008, 2008, 4932-5.		3

#	Article	IF	CITATIONS
181	Transfemoral transcatheter aortic valve implantation using the balloon expandable SAPIEN transcatheter heart valve device. Multimedia Manual of Cardiothoracic Surgery: MMCTS / European Association for Cardio-Thoracic Surgery, 2008, 2008, mmcts.2007.003087.	0.5	4
182	Assessment of \hat{l}^2 -cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E1-E15.	1.8	276
183	Surgery of Left Ventricular Aneurysm: A Meta-Analysis of Early Outcomes Following Different Reconstruction Techniques. Annals of Thoracic Surgery, 2007, 83, 2009-2016.	0.7	27
184	Identification of IVGTT minimal glucose model by nonlinear mixed-effects approaches. , 2006, 2006, 5049-52.		4
185	Identification of IVGTT minimal glucose model by nonlinear mixed-effects approaches. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2006, , .	0.5	0
186	Surgical ablation of atrial fibrillation with a novel bipolar radiofrequency device. Journal of Thoracic and Cardiovascular Surgery, 2005, 130, 491-497.	0.4	45
187	A comparison of the population pharmacokinetics of rifampicin, isoniazid and pyrazinamide between hospitalized and non-hospitalized tuberculosis patients with or without HIV. Wellcome Open Research, 0, 7, 72.	0.9	0
188	Population pharmacokinetics of esome prazole in patients with preterm preeclampsia. British Journal of Clinical Pharmacology, 0 , , .	1.1	0
189	Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy, 0, , .	1.3	3